Instrumental measurements of skin color and skin ultraviolet light sensitivity and risk of cutaneous malignant melanoma: a case-control study in an Italian population.
The authors evaluated objective measurements of constitutive skin color and ultraviolet light sensitivity in relation to risk of cutaneous malignant melanoma (CMM). Incident CMM cases (n = 183) were diagnosed between December 1994 and January 1999 at the Maurizio Bufalini Hospital in Cesena, Italy. Controls (n = 179) were mostly spouses/partners of cases and were frequency-matched by age and sex. In addition to interviews, constitutive skin color and skin ultraviolet light sensitivity were assessed by colorimetry and minimal erythema dose (MED), respectively. Odds ratios were estimated using unconditional logistic regression. The odds of CMM increased by a factor of 1.20 (95 percent confidence interval: 1.12, 1.30) for each unit of skin brightness and by a factor of 1.24 (95 percent confidence interval: 1.07, 1.43) per 10 mJ/cm(2) of MED. These associations were largely independent of phenotypic or sun-related characteristics and were modified by sun exposure. Increased risk of CMM was observed only among subjects with the highest levels of sun exposure. Epidemiologic studies of CMM may benefit from the inclusion of colorimetric and MED measurements along with traditional risk factors to obtain more accurate, quantitative, and objective information.
Brenner
Alina V
AV
Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892-7362, USA.
Lubin
Jay H
JH
Calista
Donato
D
Landi
Maria Teresa
MT
D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003124:Colorimetry; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008545:Melanoma / Q000453:epidemiology / Q000209:etiology*; D008875:Middle Aged; D012307:Risk Factors; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology*; D012880:Skin Pigmentation; D014466:Ultraviolet Rays / Q000009:adverse effects*